ZBIO

#1963
Zenas BioPharma, Inc. - Common Stock
32.7 1 USD
+0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
32.45
32.86
Jahresspanne
16.41
34.04
Tagesänderung
+2.28%
Monatliche Änderung
+1.96%
6 month change
+31.52%
Jahresänderung
+23.62%
Vorheriger Schlusskurs
31.9 8
Open
32.4 6
Tief
32.4 5
Hoch
32.8 6
Volumen
146
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Zenas Biopharma, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Zenas Biopharma, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Zenas Biopharma, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Zenas Biopharma, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Zenas Biopharma, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Zenas Biopharma, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Zenas Biopharma, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Zenas Biopharma, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Zenas Biopharma, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Zenas Biopharma, Inc. current report, Q4 FY2025
8-K

Zenas Biopharma, Inc. current report, Q4 FY2025

Full document

Zenas Biopharma, Inc. (ZBIO) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated October 7, 2025, details a strategic partnership and capital raise by Zenas Biopharma, Inc., a clinical-stage biopharmaceutical company focused on immunology and inflammation. The filing reports the entry into a material definitive license agreement with InnoCare Pharma Inc. and a concurrent private placement of equity securities.

Key Financial Metrics and Transaction Details

  • Licensing Consideration: Zenas agreed to pay InnoCare an upfront cash payment of $35 million and issued 5,000,000 shares of common stock (representing approximately 10.6% of outstanding shares post-issuance).
  • Capital Raise (PIPE): Zenas entered into a Securities Purchase Agreement to sell approximately 6.31 million shares of common stock to institutional and director/officer investors for gross proceeds of approximately $120.0 million.
  • Future Milestone Obligations:
    • Orelabrutinib: Potential near-term milestone of $25 million cash plus 2,000,000 shares; up to $723 million in additional regulatory and commercial milestones.
    • ZB021 and ZB022: Potential near-term milestones of $20 million each; up to $656 million in additional milestones per asset.
    • Royalties: Tiered royalties on net sales ranging from high-single digits to high-teens (orelabrutinib) and mid-single digits to mid-teens (ZB021/ZB022).
  • Liquidity Position: As of September 30, 2025, the company estimated approximately $302 million in cash, cash equivalents, and investments. This figure includes a $5 million deposit paid toward the InnoCare upfront payment.

Material Changes and Strategic Developments

The filing represents a significant expansion of Zenas's pipeline and financial runway:

  • Asset Acquisition: Zenas secured exclusive global rights to develop and commercialize three small molecule compounds:
    • Orelabrutinib (BTK inhibitor): Exclusive rights in Multiple Sclerosis (MS) worldwide and non-oncology indications outside Greater China and Southeast Asia.
    • ZB021 (IL-17AA/AF inhibitor): Exclusive rights worldwide, excluding Greater China and Southeast Asia.
    • ZB022 (TYK2 inhibitor): Exclusive rights worldwide.
  • Pipeline Update: The company's pipeline now comprises four programs: obexelimab, orelabrutinib, ZB021, and ZB022.
  • Ownership Structure: The issuance of shares to InnoCare and PIPE investors results in significant dilution, with InnoCare holding approximately 9.3% of the company after the PIPE issuance.

Guidance, Outlook, and Risks

Cash Runway: Management expects that, after accounting for the InnoCare upfront payment and the anticipated $120 million PIPE proceeds, cash resources will be sufficient to fund operations into the fourth quarter of 2026. This extends to the first quarter of 2027 if the company receives a potential $75 million milestone from Royalty Pharma related to the obexelimab Phase 3 INDIGO trial.

Risks and Contingencies:

  • Clinical Uncertainty: Risks related to the lengthy and expensive nature of clinical development, including potential delays or failures in trials for orelabrutinib, ZB021, and ZB022.
  • Regulatory Approval: No guarantee of regulatory approval for any product candidates.
  • Manufacturing Dependencies: Reliance on third-party manufacturers, including WuXi Biologics in China, introduces supply chain and geopolitical risks.
  • Financial Obligations: Significant future cash and equity obligations tied to regulatory and commercial milestones.

Investor Verification Checklist

  • Verify the final closing date and actual proceeds of the $120 million PIPE transaction.
  • Confirm the exact dilution impact on existing shareholders following the issuance of InnoCare and PIPE shares.
  • Review the specific terms of the "Orelabrutinib Near-Term Milestone" to understand the likelihood of the $25 million cash and 2 million share payment by March 31, 2026.
  • Assess the status of the Phase 3 INDIGO trial for obexelimab to evaluate the probability of the $75 million Royalty Pharma milestone.
  • Examine the detailed terms of the InnoCare License Agreement (Exhibit 10.1) for specific definitions of "Greater China" and "Southeast Asia" territories.